Trial Profile
A 60-week, multicentre, randomised, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 28 weeks of treatment compared to Ustekinumab and to assess long term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 30 Mar 2016 Status changed from active, no longer recruiting to completed.
- 22 Aug 2014 New trial record